• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Inspire Medical Systems Inc.

    7/2/26 4:05:06 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care
    Get the next $INSP alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Inspire Medical Systems, Inc.

    (Name of Issuer)


    Common Stock, $0.001 par value per share

    (Title of Class of Securities)




    457730109

    (CUSIP Number)
    06/25/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    457730109


    1Names of Reporting Persons

    D. E. Shaw & Co., L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,374,263.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,483,107.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,483,107.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP Number(s):
    457730109


    1Names of Reporting Persons

    David E. Shaw
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,374,263.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,483,107.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,483,107.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Inspire Medical Systems, Inc.
    (b)Address of issuer's principal executive offices:

    5500 Wayzata Blvd., Suite 1600, Golden Valley, MN 55416
    Item 2. 
    (a)Name of person filing:

    D. E. Shaw & Co., L.P. David E. Shaw
    (b)Address or principal business office or, if none, residence:

    The business address for each reporting person is: Two Manhattan West 375 Ninth Avenue, 52nd Floor New York, NY 10001
    (c)Citizenship:

    D. E. Shaw & Co., L.P. is a limited partnership organized under the laws of the state of Delaware. David E. Shaw is a citizen of the United States of America.
    (d)Title of class of securities:

    Common Stock, $0.001 par value per share
    (e)CUSIP Number(s):

    457730109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    D. E. Shaw & Co., L.P.: 1,483,107 shares This is composed of (i) 486,655 shares in the name of D. E. Shaw Valence Portfolios, L.L.C., (ii) 362,550 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C., (iii) 31,529 shares in the name of D. E. Shaw Composite Portfolios, L.L.C., and (iv) 602,373 shares under the management of D. E. Shaw Investment Management, L.L.C. David E. Shaw: 1,483,107 shares This is composed of (i) 486,655 shares in the name of D. E. Shaw Valence Portfolios, L.L.C., (ii) 362,550 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C., (iii) 31,529 shares in the name of D. E. Shaw Composite Portfolios, L.L.C., and (iv) 602,373 shares under the management of D. E. Shaw Investment Management, L.L.C. David E. Shaw does not own any shares directly. By virtue of David E. Shaw's position as President and sole shareholder of D. E. Shaw & Co., Inc., which is the general partner of D. E. Shaw & Co., L.P., which in turn is the investment adviser of D. E. Shaw Valence Portfolios, L.L.C., D. E. Shaw Oculus Portfolios, L.L.C., and D. E. Shaw Composite Portfolios, L.L.C. and the managing member of D. E. Shaw Investment Management, L.L.C., and by virtue of David E. Shaw's position as President and sole shareholder of D. E. Shaw & Co. II, Inc., which is the managing member of D. E. Shaw & Co., L.L.C., which in turn is the manager of D. E. Shaw Valence Portfolios, L.L.C., D. E. Shaw Oculus Portfolios, L.L.C., and D. E. Shaw Composite Portfolios, L.L.C., David E. Shaw may be deemed to have the shared power to vote or direct the vote of 1,374,263 shares and the shared power to dispose or direct the disposition of 1,483,107 shares, the 1,483,107 shares as described above constituting 5.1% of the outstanding shares, and, therefore, David E. Shaw may be deemed to be the beneficial owner of such shares. David E. Shaw disclaims beneficial ownership of such 1,483,107 shares.
    (b)Percent of class:

    D. E. Shaw & Co., L.P.: 5.1% David E. Shaw: 5.1%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    D. E. Shaw & Co., L.P.: 0 shares David E. Shaw: 0 shares

     (ii) Shared power to vote or to direct the vote:

    D. E. Shaw & Co., L.P.: 1,374,263 shares David E. Shaw: 1,374,263 shares

     (iii) Sole power to dispose or to direct the disposition of:

    D. E. Shaw & Co., L.P.: 0 shares David E. Shaw: 0 shares

     (iv) Shared power to dispose or to direct the disposition of:

    D. E. Shaw & Co., L.P.: 1,483,107 shares David E. Shaw: 1,483,107 shares

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    D. E. Shaw & Co., L.P.
     
    Signature:/s/ Daniel R. Marcus
    Name/Title:Daniel R. Marcus / Chief Compliance Officer
    Date:07/02/2026
     
    David E. Shaw
     
    Signature:/s/ Daniel R. Marcus
    Name/Title:Daniel R. Marcus / Attorney-in-Fact for David E. Shaw
    Date:07/02/2026

    Comments accompanying signature:  Exhibit 1: Power of Attorney, granted by David E. Shaw relating to D. E. Shaw & Co., Inc., in favor of the signatories hereto, among others, dated August 1, 2024.
    Exhibit Information

    Exhibit 2: Joint Filing Agreement, by and among the Reporting Persons, dated July 2, 2026.

    Get the next $INSP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INSP

    DatePrice TargetRatingAnalyst
    6/23/2026$40.00Outperform → In-line
    Evercore ISI
    5/22/2026$39.00Neutral → Underperform
    BofA Securities
    5/5/2026$55.00Overweight → Neutral
    Piper Sandler
    5/5/2026$53.00Buy → Neutral
    BofA Securities
    2/13/2026Outperform → Peer Perform
    Wolfe Research
    2/12/2026$74.00Outperform → Neutral
    Robert W. Baird
    2/12/2026$70.00Overweight → Equal Weight
    Wells Fargo
    1/27/2026$90.00Outperform → Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $INSP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Correction: Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on August 3, 2026

    MINNEAPOLIS, July 06, 2026 (GLOBE NEWSWIRE) -- This press release corrects the earnings release date included in the earlier version issued on July 6, 2026. No other information has changed. Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the second quarter 2026 after the close of trading on Monday, August 3. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q2 2026 earnings call webcast. For those not pl

    7/6/26 9:48:02 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on July 6, 2026

    MINNEAPOLIS, July 06, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the second quarter 2026 after the close of trading on Monday, August 3. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q2 2026 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the followin

    7/6/26 8:00:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems, Inc. Announces Presence at SLEEP 2026 and Publication of PREDICTOR Study

    MINNEAPOLIS, June 16, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced its participation in SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14–17 in Baltimore, Maryland. SLEEP is the premier global forum for sleep medicine and research, jointly hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS). Advancing Innovation and Clinical Evidence "We are pleased to return to SLEEP and showcase the continued evolution of the Inspire

    6/16/26 8:00:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Melenikiotou Georgia was granted 344 shares, increasing direct ownership by 4% to 8,329 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    7/17/26 9:28:39 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Director Tansey Casey M was granted 346 shares, increasing direct ownership by 1% to 26,632 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    7/17/26 9:27:14 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Director Ellis Gary Lee was granted 581 shares, increasing direct ownership by 5% to 11,419 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    7/17/26 9:25:34 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Curet Myriam bought $804 worth of shares (5 units at $160.72) and sold $616 worth of shares (6 units at $102.59), decreasing direct ownership by 0.03% to 3,365 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    11/24/25 8:40:17 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Sparks Charisse Y bought $15,350 worth of shares (100 units at $153.50), increasing direct ownership by 11% to 998 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    1/24/24 4:32:03 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 21, 2023 - FDA Roundup: March 21, 2023

    For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured

    3/21/23 3:12:46 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $INSP
    SEC Filings

    View All

    Inspire Medical Systems downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Inspire Medical Systems from Outperform to In-line and set a new price target of $40.00

    6/23/26 8:21:13 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems downgraded by BofA Securities with a new price target

    BofA Securities downgraded Inspire Medical Systems from Neutral to Underperform and set a new price target of $39.00

    5/22/26 8:27:02 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Inspire Medical Systems from Overweight to Neutral and set a new price target of $55.00

    5/5/26 7:02:06 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Inspire Medical Systems Inc.

    SCHEDULE 13G - Inspire Medical Systems, Inc. (0001609550) (Subject)

    7/2/26 4:05:06 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Inspire Medical Systems, Inc. (0001609550) (Filer)

    6/26/26 6:41:31 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by Inspire Medical Systems Inc.

    SD - Inspire Medical Systems, Inc. (0001609550) (Filer)

    6/1/26 9:28:03 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    Leadership Updates

    Live Leadership Updates

    View All

    Inspire Medical Systems, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Full Year 2025 and Provides Initial 2026 Revenue Guidance

    MINNEAPOLIS, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) ("Inspire", or the "Company"), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025, and provided its initial full year 2026 revenue guidance. Further, the Company announced the appointment of Matt Osberg as Executive Vice President and Chief Financial Officer. Preliminary, Unaudited Fourth Quarter and Full Year 2025 Revenue Revenue for the fourth quarter of 2025 is anticipate

    1/12/26 6:45:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems, Inc. Announces the Addition of Paul T. Hoff, M.D., M.S. and Ruchir P. Patel, M.D., F.A.C.P. as Vice President, Senior Medical Directors

    MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that two leading physicians in the field of sleep medicine and sleep surgery, Paul T. Hoff, M.D., M.S., an otolaryngologist, and Ruchir P. Patel, M.D., F.A.C.P., a sleep medicine specialist, will join Inspire in Vice President, Senior Medical Director roles, effective April 21 and June 2 respectively.   "Dr. Hoff and Dr. Patel are widely regarded as experts and thought leaders in their respective fields, a

    4/21/25 8:00:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Presidio Medical™ Announces Appointment of Richard J. Buchholz to Join its Board of Directors

    Presidio Medical, Inc., a clinical stage company developing a transformational neuromodulation platform, is pleased to announce Richard J. Buchholz will join its Board of Directors. Rick is the Chief Financial Officer of Inspire Medical Systems, Inc. (NYSE:INSP), where he has played a pivotal role in driving strategic financial and operational growth for the global leader in the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. "We are excited that Rick is joining the Board of Directors of Presidio Medical at this critical time in our company's journey. His leadership and financial acumen will be instrumental in advanc

    12/5/24 12:12:00 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    Financials

    Live finance-specific insights

    View All

    Correction: Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on August 3, 2026

    MINNEAPOLIS, July 06, 2026 (GLOBE NEWSWIRE) -- This press release corrects the earnings release date included in the earlier version issued on July 6, 2026. No other information has changed. Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the second quarter 2026 after the close of trading on Monday, August 3. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q2 2026 earnings call webcast. For those not pl

    7/6/26 9:48:02 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on July 6, 2026

    MINNEAPOLIS, July 06, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the second quarter 2026 after the close of trading on Monday, August 3. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q2 2026 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the followin

    7/6/26 8:00:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems, Inc. Announces First Quarter 2026 Financial Results and Updates 2026 Guidance

    First quarter revenue growth of 1.6%First quarter diluted EPS of $(0.39); adjusted diluted EPS of $0.10First quarter operating cash flow of $12.8 million MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the Company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2026. "Our first quarter results reflect revenue growth and improved adjusted operating income and cash flow," said Tim Herbert, Chairman and CEO of Inspire Medical Systems. "We remain focused on t

    5/4/26 4:02:00 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $INSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Inspire Medical Systems Inc.

    SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

    11/12/24 10:32:14 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Inspire Medical Systems Inc.

    SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

    10/4/24 2:09:06 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Inspire Medical Systems Inc. (Amendment)

    SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

    2/13/24 5:06:20 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care